Anti-CTLA-4 antibodies with variant Fc regions
Summary
The USPTO published patent application US20260092115A1 for anti-CTLA-4 antibodies featuring variant Fc regions and methods of production and use. The application (No. 19407391) was filed December 3, 2025, by a team of 11 inventors including researchers from pharmaceutical companies. The invention relates to therapeutic antibodies modified to enhance effector functions through Fc region engineering.
What changed
The USPTO published a patent application for anti-CTLA-4 antibodies with engineered Fc regions designed to improve therapeutic efficacy. The application covers the antibodies themselves, nucleic acids encoding them, host cells containing those nucleic acids, and methods of producing and using the polypeptides. The CPC classifications indicate applications in cancer treatment (A61P 35/00) and biotechnology processes.
Patent applications do not impose compliance deadlines or require external action from regulated entities. This publication is informational, establishing priority date and protecting intellectual property around Fc-engineered anti-CTLA-4 therapeutics. Competitors developing similar免疫检查点抑制剂 should review the claims for potential licensing needs or design-around considerations.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FC VARIANTS
Application US20260092115A1 Kind: A1 Apr 02, 2026
Inventors
Hitoshi KATADA, Kanako TATSUMI, Yutaka MATSUDA, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORI, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroaki SUSUMU
Abstract
The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region and methods of producing and using the polypeptides.
CPC Classifications
C07K 16/2818 A61P 35/00 C12N 15/63 C07K 2317/24 C07K 2317/51 C07K 2317/52 C07K 2317/92
Filing Date
2025-12-03
Application No.
19407391
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.